1262801-28-4

Basic information

• Product Name: 3-[2-{5-(5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-yl)-1,3,4-oxadiazol-2-ylthio}acetyl]-2H-chromen-2-one
• CAS NO: 1262801-28-4
• Molecular Weight: 497.531
• Mol File: 1262801-28-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-[2-{5-(5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-yl)-1,3,4-oxadiazol-2-ylthio}acetyl]-2H-chromen-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[2-{5-(5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-yl)-1,3,4-oxadiazol-2-ylthio}acetyl]-2H-chromen-2-one(1262801-28-4)
• EPA Substance Registry System: 3-[2-{5-(5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-yl)-1,3,4-oxadiazol-2-ylthio}acetyl]-2H-chromen-2-one(1262801-28-4)

Safety Data

• Hazardous Substances Data: 1262801-28-4(Hazardous Substances Data)

Upstream product

• 90-02-8 salicylaldehyde 
• 80965-09-9 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid methyl ester 
• 74103-06-3 Ketorolac 
• 3949-36-8 3-acetylcoumarin 
• 29310-88-1 3-bromoacetylcoumarin 
• 1262801-33-1 C₁₆H₁₃N₃O₂S 

Relevant articles and documents

Synthesis and evaluation of anti-inflammatory and analgesic activity of 3-[(5-substituted-1,3,4-oxadiazol-2-yl-thio)acetyl]-2H-chromen-2-ones

A novel series of 3-[(5-substituted-1,3,4-oxadiazol- 2-yl-thio)acetyl]-2H- chromen-2-one (7a-i) were synthesized by the condensation between the appropriately substituted 5-substituted-1,3,4-oxadiazolyl-2-thione (4a-i) derived from various existing NSAIDs and 3-(2-bromoacetyl)- 2H-chromen-2-one (6) under reflux in the presence of sodium ethoxide. Structure of the synthesized compounds was established on the basis of physicochemical, elemental analysis, and spectral data. The title compounds were screened for in vivo acute anti-inflammatory and analgesic activities at a dose of 200 mg/kg bw. Among the series, four compounds 7c, 7e, 7f, and 7h were found to possess a significant anti-inflammatory and analgesic activity profile. In addition, these compounds were also found to possess a less degree of ulcerogenic potential as compared to standard NSAIDs. Springer Science+Business Media, LLC 2010.